FDA grants Orphan Drug Designation to SignaBlok’s first-in-class, new mechanism-based TREM-1 peptide inhibitor to treat retinopathy of prematurity “Orphan Drug Designation for ROP represents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results